Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

  • Snapshot
    • A 45-year-old woman presents to the emergency room with painless vision loss. She has a past medical history of HIV infection and has not been on any anti-retroviral medications due to loss of health insurance last year. Her course has been complicated by CMV esophagitis in the past, which was resistant to ganciclovir. Her last CD4+ count was < 50/uL 1 week ago. On physical exam, she is found to be dehydrated with decreased skin turgor and dry mucous membranes. Funduscopic exam shows yellow-white patches of retinal opacification. After fluid resuscitation, she is started on foscarnet. (CMV retinitis)
  • Introduction
    • Drugs
      • foscarnet
    • Mechanism of action
      • inhibits viral DNA/RNA polymerase and HIV reverse transcriptase by preventing pyrophosphate from binding
        • the drug is a pyrophosphate (pyroFOSphate, FOScarnet) analog
        • does not need to be activated by a kinase
          • can be used in viral strains resistant to acyclovir and ganciclovir
    • Mechanism of resistance
      • mutation of viral DNA/RNA polymerase
    • Clinical use
      • cytomegalovirus (CMV) infections in immunocompromised patients (e.g., HIV)
        • especially if resistant to ganciclovir
        • can also be given in combination with ganciclovir
      • herpes simplex virus infections
        • especially if resistant to acyclovir
      • varicella zoster virus infections
    • Adverse effects
      • nephrotoxic
        • must correct dehydration prior to therapy
        • acute tubular necrosis
      • cardiac effects
        • QT prolongation
        • torsades de pointes
      • electrolyte abnormalities
        • hypocalcemia
        • hypomagnesemia
        • seizures
1 of 0
Private Note

Attach Treatment Poll
Treatment poll is required to gain more useful feedback from members.
Please enter Question Text
Please enter at least 2 unique options
Please enter at least 2 unique options
Please enter at least 2 unique options